Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantatio
Recruiting
- Conditions
- Aortic Valve Stenosis
- Registration Number
- NL-OMON26988
- Lead Sponsor
- St Antonius Hospital, Nieuwegein, the Netherlands
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 858
Inclusion Criteria
Planned transfemoral transcatheter aortic valve implantation procedure
- Established indication for oral anticoagulation
- Written informed consent
Exclusion Criteria
Patients at high risk for thromboembolism for who interruption of oral anticoagulants is no option:
- Mechanical heart valve prosthesis
- Intracardiac thrombus
< 3 months after venous thromboembolism
< 6 months after transient ischemic attack or stroke in patients with atrial fibrillation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of oral anticoagulants in transcatheter aortic valve implantation (TAVI) patients with aortic valve stenosis?
How does periprocedural continuation of anticoagulants compare to interruption in terms of efficacy and safety for TAVI in aortic valve stenosis patients?
Which biomarkers are associated with optimal patient selection for anticoagulant continuation during TAVI in aortic valve stenosis?
What are the potential adverse events of anticoagulant interruption during TAVI and how are they managed in clinical practice?
Are there alternative anticoagulant strategies or combination therapies being explored for TAVI in aortic valve stenosis compared to NL-OMON26988?